<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666845</url>
  </required_header>
  <id_info>
    <org_study_id>H-1807-153-961</org_study_id>
    <nct_id>NCT03666845</nct_id>
  </id_info>
  <brief_title>Plasma Ropivacaine Concentrations After Sciatic Nerve Block in Patients With Chronic Kidney Disease</brief_title>
  <official_title>Plasma Ropivacaine Concentrations After Peripheral Nerve Block in Patients With Severe Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational study aimed to examine the pharmacokinetics of ropivacaine in&#xD;
      patients with chronic kidney disease after sciatic nerve block.&#xD;
&#xD;
      Sciatic nerve block for foot and ankle surgery will be performed using ropivacaine under&#xD;
      ultrasound-guidance, and arterial blood test will be taken for total plasma ropivacaine&#xD;
      concentration at 2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of unbound ropivacaine</measure>
    <time_frame>2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block</time_frame>
    <description>whether the unbound plasma concentration of ropivacaine was maintained under 0.56 mcg/ml that was determined as toxic level in a previous study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of 3-OH-ropivacaine</measure>
    <time_frame>2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block</time_frame>
    <description>metabolite of ropivacaine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of pipecoloxylidide</measure>
    <time_frame>2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block</time_frame>
    <description>metabolite of ropivacaine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>2, 6, 24 hours after sciatic nerve block</time_frame>
    <description>11-point numeric rating scale ranging from '0' representing one extreme (e.g. &quot;extremely dissatisfied&quot;) to '10' representing the other extreme (e.g. &quot;extremely satisfied&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local anesthetic systemic toxicity</measure>
    <time_frame>2, 6, 24 hours after sciatic nerve block</time_frame>
    <description>numbness of the tongue, twitching, convulsion, dysarrhythmia, coma</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Regional Anesthesia Morbidity</condition>
  <condition>Local Anesthetic Drug Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Sciatic nerve block</arm_group_label>
    <description>Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic kidney disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sciatic nerve block</intervention_name>
    <description>Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.</description>
    <arm_group_label>Sciatic nerve block</arm_group_label>
    <other_name>Popliteal block</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Arterial blood sampling will be taken at 2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after&#xD;
      sciatic nerve block.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic&#xD;
        kidney disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for foot and ankle surgery&#xD;
&#xD;
          -  Patients with chronic kidney disease (glomerular filtration rate &lt; 60 ml/min/1.73m2)&#xD;
             (changed from 30 ml/min/1.73m2 to facilitate patient recruitment)&#xD;
&#xD;
          -  Patients who are thought to be clinically helpful to receive sciatic nerve block&#xD;
             rather than general anesthesia because of comorbidities such as cardiopulmonary&#xD;
             dysfunction and cerebral dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who need to renal replacement therapy, such as hemodialysis&#xD;
&#xD;
          -  Patients with liver disease (aspartate transaminase OR alanine transaminase &gt; 80 IU/L)&#xD;
&#xD;
          -  Patients with allergic disease&#xD;
&#xD;
          -  Patients with previous history of drug allery&#xD;
&#xD;
          -  Patients with chronic pain persisting 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Tae Kim, Pf.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Tae Kim, Pf.</last_name>
    <phone>+82-2-2072-3592</phone>
    <email>jintae73@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Tae Kim, Pf.</last_name>
      <phone>+82-2-2072-3295</phone>
      <email>jintae73@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin-Tae Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

